TD Asset Management
ARQT icon

TD Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

TD Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-97,200
Closed -$2.82M – 1236
2025
Q4 		$2.82M Buy
+97,200
New +$2.49M ﹤0.01% 909
2022
Q1 		– Sell
-35,920
Closed -$745K – 1485
2021
Q4 		$745K Buy
35,920
+5,410
+18% +$108K ﹤0.01% 1330
2021
Q3 		$729K Hold
30,510
– – ﹤0.01% 1321
2021
Q2 		$712K Sell
30,510
-3,145
-9% -$88.6K ﹤0.01% 1334
2021
Q1 		$974K Buy
33,655
+25,100
+293% +$784K ﹤0.01% 1265
2020
Q4 		$241K Sell
8,555
-11,919
-58% -$292K ﹤0.01% 1410
2020
Q3 		$600K Hold
20,474
– – ﹤0.01% 1198
2020
Q2 		$619K Hold
20,474
– – ﹤0.01% 1172
2020
Q1 		$610K Buy
+20,474
New +$550K ﹤0.01% 1123

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return